Navigation Links
Phase 2b Data Suggest ReVision's Oral Fenretinide (RT-101) Slows Lesion Growth, Preserves Vision and Reduces Incidence of Neovascularization in Geographic Atrophy Patients
Date:10/18/2010

nd induction of angiogenic mediators has been implicated in risk and progression of wet AMD. Fenretinide limits the delivery of retinol to the eye through reduction of serum RBP. This slows the accumulation of retinol-derived toxins in the retina, thereby slowing lesion growth. The anti-inflammatory and anti-angiogenic properties of fenretinide are thought to provide an additional therapeutic benefit against development of wet AMD.

About ReVision Therapeutics

ReVision Therapeutics Inc. is an ophthalmic biopharmaceutical company developing a novel small-molecule drug to slow the progression of the dry form of age-related macular degeneration (AMD) and prevent wet AMD. Fenretinide (RT-101), ReVision's lead drug candidate, showed a positive treatment effect for both slowing lesion growth in dry AMD and reducing the incidence of wet AMD in a Phase 2b clinical trial in patients with geographic atrophy, the most advanced form of dry AMD. The company plans to initiate a pivotal Phase 3 trial after discussion with the FDA. AMD is the leading cause of blindness in the elderly, and there are currently no treatments for the dry form of AMD, which accounts for 90 percent of patients with the disease. Dry AMD gradually destroys sharp, central vision. Most cases of wet AMD are preceded by dry AMD, and the onset of wet AMD can cause rapid blindness. ReVision was founded in 2010 with corporate headquarters in San Diego, California. For more information, visit www.revisiontherapeutics.com

Media Contact
Heidi Chokeir, Ph.D.
Russo Partners, LLC
(858)380-6584
heidi.chokeir@russopartnersllc.com




'/>"/>
SOURCE ReVision Therapeutics Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3

Related medicine technology :

1. Kaiser Permanentes ALL/PHASE Initiative Wins 2010 Care Continuum Alliance Quality Impact Award for Greatest Impact on Health
2. BioSpecifics Technologies Corp. Announces Initiation of Global Phase 3 Trial of XIAFLEX® for Treatment of Peyronies Disease
3. Titan Pharmaceuticals Announces Journal of the American Medical Association Publication of Phase 3 Probuphine™ Data
4. Albireo Announces Positive Results in Patients With Chronic Idiopathic Constipation From a Phase IIb trial of A3309
5. DATATRAK Awarded Three Phase III Studies
6. BiondVax Begins Phase IIa Study for Universal Flu Vaccine
7. Auxilium Pharmaceuticals, Inc. Announces Initiation of XIAFLEX® Phase III Studies for Peyronies Disease
8. Obstetrics and Gynecology Publishes Data From Pivotal Phase 3 LYSTEDA Study
9. ISTA Pharmaceuticals Reports Positive Preliminary Results from its Phase 1/2 Clinical Study of Bepotastine Besilate Nasal Spray for the Treatment of Symptoms Associated with Seasonal Allergic Rhinitis
10. New Details Presented at the World Parkinson Congress on Neurologixs Successful Phase 2 Trial of Gene Therapy for Parkinsons Disease
11. Phase III Data Showing Improved Survival With Jevtana® (cabazitaxel) Injection in Second-Line Advanced Prostate Cancer Published in The Lancet
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/15/2014)... , Jan. 15, 2014  According to Millennium Research ... market intelligence, the United States ... device markets will expand moderately through 2022, with ... In particular, increasing interest in drug-eluting beads (DEBs) ...
(Date:1/15/2014)... Jan. 15, 2014 Reportlinker.com announces ... is available in its catalogue: ... Technologies for Advanced Drug Delivery Systems ... http://www.reportlinker.com/p01941928/Global-Markets-and-Technologies-for-Advanced-Drug-Delivery-Systems----Focus-on-Routes-of-Administration.html#utm_source=prnewswire&utm_medium=pr&utm_campaign=Drug_Delivery_Technology ...
(Date:1/14/2014)... Jan. 14, 2014 InformEx, North America,s ... high-value chemistry, will hold the 30 th edition of ... Convention Center from January 21-24. (Logo: ... top pharmaceutical, fine chemical and specialty chemical companies will take ...
Breaking Medicine Technology:US and European Transcatheter Embolization and Occlusion Device Market to Surpass $1.6 Billion by 2022 2US and European Transcatheter Embolization and Occlusion Device Market to Surpass $1.6 Billion by 2022 3Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on Routes of Administration 2Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on Routes of Administration 3Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on Routes of Administration 4Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on Routes of Administration 5Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on Routes of Administration 6Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on Routes of Administration 7Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on Routes of Administration 8Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on Routes of Administration 9Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on Routes of Administration 10Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on Routes of Administration 11Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on Routes of Administration 12Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on Routes of Administration 13Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on Routes of Administration 14Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on Routes of Administration 15Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on Routes of Administration 16Media Advisory: InformEx 2014 Events & Speaker Lineup for 30th Edition Conference in Miami Beach 2
(Date:4/17/2014)... a study published today in PLOS Pathogens , ... malaria is common can mount an immune response to ... avoid repeated bouts of high fever and illness and ... bloodstream. The findings may help researchers develop future interventions ... malaria parasite. , Each year, approximately 200 million cases ...
(Date:4/17/2014)... of California, San Diego School of Medicine report that ... a recent major loss are more likely to be ... study is published in this month,s issue of the ... compassionate behaviors are associated with better health and well-being ... ways to improve the outcomes of individuals whose deficits ...
(Date:4/17/2014)... NY In a review published in the April ... president of The Feinstein Institute for Medical Research, says ... medical community,s approach to treating sepsis, which ... Americans. , Sepsis occurs when molecules released into the ... throughout the body. Inflammation is necessary for maintaining good ...
(Date:4/17/2014)... biology team has created a new technology for ... could travel the body and selectively target cancer ... biological devices that monitor and modify human physiology ... However, no existing technology enabled bioengineers to build ... and respond in a customized fashion. , "The ...
(Date:4/17/2014)... Il. (April 17, 2014) Doctors who treat ... called lymphangioleiomyomatosis (LAM) can face an agonizing treatment ... of the disease and help relieve shortness of ... transplants, and sirolimus can cause potentially fatal complications ... pulmonologist Dr. Daniel Dilling, medical director of Loyola ...
Breaking Medicine News(10 mins):Health News:Study sheds light on how the immune system protects children from malaria 2Health News:The ilk of human kindness 2Health News:Feinstein Institute researcher publishes new perspective on sepsis 2Health News:Building 'smart' cell-based therapies 2Health News:Patients with rare lung disease face agonizing treatment dilemma 2Health News:Patients with rare lung disease face agonizing treatment dilemma 3
... in Mexico support innovations to extend the local, productive impact of remittances shines spotlight ... ... Mexico and the US. - Broad, support in communities of origin for the ... from the US. -, Family members in Mexico would encourage senders to ...
... bill pending in the,state Senate could address Pennsylvania,s ... thousands who lack health insurance, a top Department,of ... Joined by approximately 250 nursing students and ... Bureau of Professional and,Occupational Affairs Commissioner Basil Merenda ...
... Touch with Reality, MANHATTAN BEACH, Calif., May 7 ... began in 2006 continues,today with open hearings and fact-finding ... of examining how homecare and nursing home,workers in the ... have the greatest strength to win for their families ...
... Final results of sub-analyses of dose-titration study and long-term, ... open-label study presented today, ... seen in children, Attention Deficit Hyperactivity Disorder,(ADHD) is now known to ... the lifespan(1). In the US, the overall,prevalence of ADHD in adults ...
... For the first time, researchers from the University of ... dendritic cells that are key to asthma and allergy-related ... more effective drugs to treat allergic disorders and asthma, ... of the journal Nature Medicine. , Dendritic cells are ...
... on Hemoglobin-Based Oxygen Carriers Indicates Support for Continued ... Investigational Use Where Blood Is Not an Option, ... BPUR ) announced today that the Company,s strategy to ... HBOC-201, when blood is not an option was reinforced ...
Cached Medicine News:Health News:Recipients in Mexico Favor Receiving US-Sent Remittances Through Companies that Contribute to Local Economic Development and Job Creation Projects 2Health News:Recipients in Mexico Favor Receiving US-Sent Remittances Through Companies that Contribute to Local Economic Development and Job Creation Projects 3Health News:Providing Affordable Health Care Coverage Cited as a Top Priority, Commissioner Says 2Health News:Open Hearings, Fact-Finding Today by SEIU Long Term Care Workers Continues Democratic Process Begun in 2006 2Health News:OROS(R) Methylphenidate in Adults with ADHD: New Insights 2Health News:OROS(R) Methylphenidate in Adults with ADHD: New Insights 3Health News:OROS(R) Methylphenidate in Adults with ADHD: New Insights 4Health News:OROS(R) Methylphenidate in Adults with ADHD: New Insights 5Health News:OROS(R) Methylphenidate in Adults with ADHD: New Insights 6Health News:Immune system pathway identified to fight allergens, asthma 2Health News:Biopure Reaffirms Strategy Following Recent NIH/FDA Workshop 2Health News:Biopure Reaffirms Strategy Following Recent NIH/FDA Workshop 3Health News:Biopure Reaffirms Strategy Following Recent NIH/FDA Workshop 4
An intermediate set providing a greater range of telescopes than the starter set....
Significantly more compact and tidier in overall looks yet retain many of the excellent features of the more comprehensive Haag type systems., ,Filters include Cobalt blue; green (red free); neut...
... up to 20 tilting ... in the vertical, horizontal ... the option to offset ... transillumination., ,Filters include Cobalt ...
With a high lens and filter range this ophthalmoscope is ideal for the Primary Care Specialist...
Medicine Products: